FY2025 Earnings Forecast for CNTB Issued By Northland Capmk

Key Points

• Northland Capmk has lowered its FY2025 earnings forecast for Connect Biopharma to ($0.92) per share, compared to a previous estimate of ($0.90).
• HC Wainwright maintains a "buy" rating for the stock with a price target of $7.00, while the consensus rating is "Strong Buy."
• Connect Biopharma's stock is currently trading at $1.56, having a significant trading range between a 12-month low of $0.51 and a high of $2.86.

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - Research analysts at Northland Capmk decreased their FY2025 earnings estimates for shares of Connect Biopharma in a research report issued on Thursday, September 11th. Northland Capmk analyst C. Byrnes now anticipates that the company will earn ($0.92) per share for the year, down from their previous forecast of ($0.90). Northland Capmk has a "Strong-Buy" rating on the stock. The consensus estimate for Connect Biopharma's current full-year earnings is ($0.22) per share.

Other analysts also recently issued reports about the company. HC Wainwright restated a "buy" rating and issued a $7.00 price target on shares of Connect Biopharma in a research note on Wednesday, August 13th. Wall Street Zen raised Connect Biopharma to a "hold" rating in a report on Friday, August 22nd. One analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Strong Buy" and a consensus target price of $7.00.

Connect Biopharma Trading Down 4.3%

Connect Biopharma stock opened at $1.56 on Monday. The company has a quick ratio of 7.24, a current ratio of 7.24 and a debt-to-equity ratio of 0.01. Connect Biopharma has a 12 month low of $0.51 and a 12 month high of $2.86. The stock's 50 day moving average is $1.86 and its 200-day moving average is $1.18.

Hedge Funds Weigh In On Connect Biopharma

Several institutional investors have recently added to or reduced their stakes in CNTB. XTX Topco Ltd bought a new position in shares of Connect Biopharma during the 2nd quarter worth approximately $29,000. AlphaCore Capital LLC acquired a new position in shares of Connect Biopharma during the 2nd quarter valued at $78,000. Finally, Koa Wealth Management LLC acquired a new position in shares of Connect Biopharma during the 2nd quarter valued at $49,000. 58.72% of the stock is owned by institutional investors and hedge funds.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.